Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm.

Trial Profile

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Blepharospasm
  • Focus Registrational; Therapeutic Use
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 25 Oct 2011 Results from the long-term extension will be presented at the 115th Annual Meeting of the American Academy of Ophthalmology (AAO).
    • 05 Nov 2010 Results will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, according to a Merz Pharmaceuticals media release.
    • 28 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top